Medications not yet evaluated by P&T are considered NON-FORMULARY . . . . . Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step! . . . . . Please be sure to document all clinical activities daily.
Search results for:

upadacitinib

upadacitinib
Drug Name Form Strength Formulary Unrestricted Formulary Restricted Non-Formulary Interchange
Rinvoq SOLUTION, ORAL 1 mg/mL      
Rinvoq TABLET, ORAL 15 mg, 30 mg, 45 mg      
Comments:

Non-Formulary. Inpatients should use their own supply.

 

 

 

 

 

 

 

Reviewed: January 2026          

Upadacitinib (RINVOQ) Spotlight 2025.pdf

Last updated: Feb. 21, 2026
Rhazdrugs upadacitinib






This site is intended for the staff of Huntsville Hospital.
While others may view accessible pages, Huntsville Hospital makes no warranty, express or implied,
as to the use of this information outside of Huntsville Hospital.
Please note than many documents are accessible via the provided link
only when connected to the Huntsville Hospital intranet.

Copyright © 2026 Rpharmy, LLC ­ All Rights Reserved